Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease

Katsuyoshi Matsuoka, Shunsuke Hamada, Mikiko Shimizu, Kosaku Nanki, Shinta Mizuno, Hiroki Kiyohara, Mari Arai, Shinya Sugimoto, Yasushi Iwao, Haruhiko Ogata, Tadakazu Hisamatsu, Makoto Naganuma, Takanori Kanai, Mayumi Mochizuki, Masayuki Hashiguchi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Since anti-tumor necrosis factor (TNF)-α agents (TNF-α inhibitors) induce both clinical response and remission in patients with moderate to severe inflammatory bowel disease (IBD), the use of anti-TNF therapies has fundamentally changed the approach to treatment for patients with IBD. Infliximab (IFX) is a TNF-α inhibitor approved for the induction and remission of Crohn's disease (CD). However, even among patients who initially demonstrate a clinical response to IFX therapy, secondary loss of response occurs, although the reason remains unknown. We therefore investigated predictive factors associated with the response to IFX in long-term maintenance treatment in Japanese CD patients. Eight types of single-nucleotide polymorphisms (SNPs) were investigated using the real-time PCR method, and patient characteristics were collected from the electronic medical records. The Crohn's Disease Activity Index criteria were used as the response to IFX therapy. The observation period was 1 year after IFX had been administered for more than 1 year. Associations between the IFX response and patient characteristics were evaluated using the multivariate logistic regression model. We studied 121 unrelated adult Japanese with CD treated for more than 1 year with IFX as outpatients at Keio University Hospital from November 1, 2014 to November 30, 2015. Among them, 71 were classified as in remisson. In multivariate analysis, patients with the TNF-α 857C>T C/C genotype, shorter disease duration, without double dosing, and combination treatment with an immunomodulator had higher remisson rates than those with the C/T or T/T genotype, longer disease duration, with double dosing, and no combination treatment with an immunomodulator. The response to IFX in Japanese CD patients may therefore be predicted by these 4 characteristics in actual clinical practice.

Original languageEnglish
Article numbere0204632
JournalPLoS One
Volume13
Issue number10
DOIs
Publication statusPublished - 2018 Oct 1

Fingerprint

Crohn disease
Crohn Disease
tumor necrosis factors
therapeutics
Tumor Necrosis Factor-alpha
immunomodulators
Immunologic Factors
Therapeutics
inflammatory bowel disease
Inflammatory Bowel Diseases
remission
Logistic Models
Genotype
Remission Induction
Electronic medical equipment
Infliximab
Electronic Health Records
duration
genotype
Polymorphism

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease. / Matsuoka, Katsuyoshi; Hamada, Shunsuke; Shimizu, Mikiko; Nanki, Kosaku; Mizuno, Shinta; Kiyohara, Hiroki; Arai, Mari; Sugimoto, Shinya; Iwao, Yasushi; Ogata, Haruhiko; Hisamatsu, Tadakazu; Naganuma, Makoto; Kanai, Takanori; Mochizuki, Mayumi; Hashiguchi, Masayuki.

In: PLoS One, Vol. 13, No. 10, e0204632, 01.10.2018.

Research output: Contribution to journalArticle

Matsuoka, Katsuyoshi ; Hamada, Shunsuke ; Shimizu, Mikiko ; Nanki, Kosaku ; Mizuno, Shinta ; Kiyohara, Hiroki ; Arai, Mari ; Sugimoto, Shinya ; Iwao, Yasushi ; Ogata, Haruhiko ; Hisamatsu, Tadakazu ; Naganuma, Makoto ; Kanai, Takanori ; Mochizuki, Mayumi ; Hashiguchi, Masayuki. / Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease. In: PLoS One. 2018 ; Vol. 13, No. 10.
@article{caf94b2bcf7f4bcebdbaba6972471584,
title = "Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease",
abstract = "Since anti-tumor necrosis factor (TNF)-α agents (TNF-α inhibitors) induce both clinical response and remission in patients with moderate to severe inflammatory bowel disease (IBD), the use of anti-TNF therapies has fundamentally changed the approach to treatment for patients with IBD. Infliximab (IFX) is a TNF-α inhibitor approved for the induction and remission of Crohn's disease (CD). However, even among patients who initially demonstrate a clinical response to IFX therapy, secondary loss of response occurs, although the reason remains unknown. We therefore investigated predictive factors associated with the response to IFX in long-term maintenance treatment in Japanese CD patients. Eight types of single-nucleotide polymorphisms (SNPs) were investigated using the real-time PCR method, and patient characteristics were collected from the electronic medical records. The Crohn's Disease Activity Index criteria were used as the response to IFX therapy. The observation period was 1 year after IFX had been administered for more than 1 year. Associations between the IFX response and patient characteristics were evaluated using the multivariate logistic regression model. We studied 121 unrelated adult Japanese with CD treated for more than 1 year with IFX as outpatients at Keio University Hospital from November 1, 2014 to November 30, 2015. Among them, 71 were classified as in remisson. In multivariate analysis, patients with the TNF-α 857C>T C/C genotype, shorter disease duration, without double dosing, and combination treatment with an immunomodulator had higher remisson rates than those with the C/T or T/T genotype, longer disease duration, with double dosing, and no combination treatment with an immunomodulator. The response to IFX in Japanese CD patients may therefore be predicted by these 4 characteristics in actual clinical practice.",
author = "Katsuyoshi Matsuoka and Shunsuke Hamada and Mikiko Shimizu and Kosaku Nanki and Shinta Mizuno and Hiroki Kiyohara and Mari Arai and Shinya Sugimoto and Yasushi Iwao and Haruhiko Ogata and Tadakazu Hisamatsu and Makoto Naganuma and Takanori Kanai and Mayumi Mochizuki and Masayuki Hashiguchi",
year = "2018",
month = "10",
day = "1",
doi = "10.1371/journal.pone.0204632",
language = "English",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease

AU - Matsuoka, Katsuyoshi

AU - Hamada, Shunsuke

AU - Shimizu, Mikiko

AU - Nanki, Kosaku

AU - Mizuno, Shinta

AU - Kiyohara, Hiroki

AU - Arai, Mari

AU - Sugimoto, Shinya

AU - Iwao, Yasushi

AU - Ogata, Haruhiko

AU - Hisamatsu, Tadakazu

AU - Naganuma, Makoto

AU - Kanai, Takanori

AU - Mochizuki, Mayumi

AU - Hashiguchi, Masayuki

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Since anti-tumor necrosis factor (TNF)-α agents (TNF-α inhibitors) induce both clinical response and remission in patients with moderate to severe inflammatory bowel disease (IBD), the use of anti-TNF therapies has fundamentally changed the approach to treatment for patients with IBD. Infliximab (IFX) is a TNF-α inhibitor approved for the induction and remission of Crohn's disease (CD). However, even among patients who initially demonstrate a clinical response to IFX therapy, secondary loss of response occurs, although the reason remains unknown. We therefore investigated predictive factors associated with the response to IFX in long-term maintenance treatment in Japanese CD patients. Eight types of single-nucleotide polymorphisms (SNPs) were investigated using the real-time PCR method, and patient characteristics were collected from the electronic medical records. The Crohn's Disease Activity Index criteria were used as the response to IFX therapy. The observation period was 1 year after IFX had been administered for more than 1 year. Associations between the IFX response and patient characteristics were evaluated using the multivariate logistic regression model. We studied 121 unrelated adult Japanese with CD treated for more than 1 year with IFX as outpatients at Keio University Hospital from November 1, 2014 to November 30, 2015. Among them, 71 were classified as in remisson. In multivariate analysis, patients with the TNF-α 857C>T C/C genotype, shorter disease duration, without double dosing, and combination treatment with an immunomodulator had higher remisson rates than those with the C/T or T/T genotype, longer disease duration, with double dosing, and no combination treatment with an immunomodulator. The response to IFX in Japanese CD patients may therefore be predicted by these 4 characteristics in actual clinical practice.

AB - Since anti-tumor necrosis factor (TNF)-α agents (TNF-α inhibitors) induce both clinical response and remission in patients with moderate to severe inflammatory bowel disease (IBD), the use of anti-TNF therapies has fundamentally changed the approach to treatment for patients with IBD. Infliximab (IFX) is a TNF-α inhibitor approved for the induction and remission of Crohn's disease (CD). However, even among patients who initially demonstrate a clinical response to IFX therapy, secondary loss of response occurs, although the reason remains unknown. We therefore investigated predictive factors associated with the response to IFX in long-term maintenance treatment in Japanese CD patients. Eight types of single-nucleotide polymorphisms (SNPs) were investigated using the real-time PCR method, and patient characteristics were collected from the electronic medical records. The Crohn's Disease Activity Index criteria were used as the response to IFX therapy. The observation period was 1 year after IFX had been administered for more than 1 year. Associations between the IFX response and patient characteristics were evaluated using the multivariate logistic regression model. We studied 121 unrelated adult Japanese with CD treated for more than 1 year with IFX as outpatients at Keio University Hospital from November 1, 2014 to November 30, 2015. Among them, 71 were classified as in remisson. In multivariate analysis, patients with the TNF-α 857C>T C/C genotype, shorter disease duration, without double dosing, and combination treatment with an immunomodulator had higher remisson rates than those with the C/T or T/T genotype, longer disease duration, with double dosing, and no combination treatment with an immunomodulator. The response to IFX in Japanese CD patients may therefore be predicted by these 4 characteristics in actual clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85054462719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054462719&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0204632

DO - 10.1371/journal.pone.0204632

M3 - Article

C2 - 30286108

AN - SCOPUS:85054462719

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e0204632

ER -